Trending: Roche Guides for 2023 Sales, Earnings Decline on Covid-19 Drop
February 03 2023 - 2:24AM
Dow Jones News
1452 GMT - Roche Holding AG is among the most mentioned
companies across news items over the past 12 hours, according to
Factiva data, after the company's 2022 profit missed expectations
and guided for lower sales and earnings in 2023 due to declining
Covid-19 sales. The Swiss pharma major's 2022 sales rose on-year
and were in line with consensus, though its net profit dropped and
missed expectations. It confirmed a CHF5 billion hit from missed
Covid-19 product sales as previously announced. For the year ahead,
it said it expects a drop in sales in the low-single digits at
constant exchange rates, with earnings per share set to develop in
line with the sales decline. Excluding Covid-19 sales decline,
Roche expects underlying sales growth in both its divisions. It
said it would also further increase its dividend. Dow Jones &
Co. owns Factiva. (cecilia.butini@wsj.com)
(END) Dow Jones Newswires
February 02, 2023 10:08 ET (15:08 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Jul 2023 to Jul 2024